Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 58, Issue 3, Pages 909-918Publisher
IOS PRESS
DOI: 10.3233/JAD-170073
Keywords
Alzheimer's disease; biomarkers; cerebrospinal fluid; episodic memory; mild cognitive impairment; mild neurocognitive disorder; neuropsychological test
Categories
Funding
- Carlos III Institute of Health, Spain [PI11/02425, PI14/01126, PI10/1878, PI13/01532, PI11/03035, PI14/1561]
- CIBERNED program - Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Una manera de hacer Europa
- Marato TV3 grant [20141210]
- Generalitat de Catalunya [2014SGR-0235]
- i-PFIS from the FIS, Instituto de Salud Carlos III [IF15/00060]
- Carlos III Institute of Health, Spain [PI11/02425, PI14/01126, PI10/1878, PI13/01532, PI11/03035, PI14/1561]
- CIBERNED program - Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Una manera de hacer Europa
- Marato TV3 grant [20141210]
- Generalitat de Catalunya [2014SGR-0235]
- i-PFIS from the FIS, Instituto de Salud Carlos III [IF15/00060]
Ask authors/readers for more resources
Background: Episodic memory impairment is the core feature of typical Alzheimer's disease. Objective: To evaluate the performance of two commonly used verbal memory tests to detect mild cognitive impairment due to Alzheimer's disease (MCI-AD) and to predict progression to Alzheimer's disease dementia (AD-d). Methods: Prospective study of MCI patients in a tertiary memory disorder unit. Patients underwent an extensive neuropsychological battery including two tests of declarative verbal memory: The Free and Cued Selective Reminding Test (FCSRT) and the word list learning task from the Consortium to Establish a Registry for Alzheimer's disease (CERAD-WL). Cerebrospinal fluid (CSF) was obtained from all patients and MCI-AD was defined by means of the t-Tau/A beta(1-42) ratio. Logistic regression analyses tested whether the combination of FCSRT and CERAD-WL measures significantly improved the prediction of MCI-AD. Progression to AD-d was analyzed in a Cox regression model. Results: A total of 202 MCI patients with a mean follow-up of 34.2 +/- 24.2 months were included and 98 (48.5%) met the criteria for MCI-AD. The combination of FCSRT and CERAD-WL measures improved MCI-AD classification accuracy based on CSF biomarkers. Both tests yielded similar global predictive values (59.9-65.3% and 59.4-62.8% for FCSRT and CERAD-WL, respectively). MCI-AD patients with deficits in both FCSRT and CERAD-WL had a faster progression to AD-d than patients with deficits in only one test. Conclusions: The combination of FCSRT and CERAD-WL improves the classification of MCI-AD and defines different prognostic profiles. These findings have important implications for clinical practice and the design of clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available